http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html <p align="justify">TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.</p> <p align="justify">Interested parties can access the live presentation through the following link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=oZxnyyxmH4mzOiXakKWeioP9mUjoKDxIngIbjjKxQGLBK-IXi3iRIaJI_KJcWJWr29R0M2VhGmp_RZo_tDBlcUXYq1cw87Urn2l_1rjYR2HRXTf1CKnNuDvUemxuUat3v1sDTnG-wXjQSvQfP1OeEI4ZqbYQtnA2u7tQenn0P1k=" rel="nofollow" target="_blank">Access Live Presentation</a></p> <p align="justify">The Company will also participate in one-on-one meetings at the virtual http://www.streetinsider.com/Globe+Newswire/NetraMark+Announces+Presentation+at+Sidoti+Small+Cap+Conference+on+June+18%2C+2026/26620048.html Tue, 09 Jun 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0